Cargando…

The value of breast MRI in high‐risk patients with newly diagnosed breast cancer to exclude invasive disease in the contralateral prophylactic mastectomy: Is there a role to choose wisely patients for sentinel node biopsy?

The aim of this study was to evaluate the presence of clinically and mammographically occult disease using breast MRI in a cohort of cancer patients undergoing contralateral prophylactic mastectomy (CPM) and the utmost indication of axillary assessment (sentinel node biopsy (SLNB)) for this side. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Freitas, Vivianne, Crystal, Pavel, Kulkarni, Supriya R., Ghai, Sandeep, Bukhanov, Karina, Escallon, Jaime, Scaranelo, Anabel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924360/
https://www.ncbi.nlm.nih.gov/pubmed/26992816
http://dx.doi.org/10.1002/cam4.663
_version_ 1782439858496602112
author Freitas, Vivianne
Crystal, Pavel
Kulkarni, Supriya R.
Ghai, Sandeep
Bukhanov, Karina
Escallon, Jaime
Scaranelo, Anabel M.
author_facet Freitas, Vivianne
Crystal, Pavel
Kulkarni, Supriya R.
Ghai, Sandeep
Bukhanov, Karina
Escallon, Jaime
Scaranelo, Anabel M.
author_sort Freitas, Vivianne
collection PubMed
description The aim of this study was to evaluate the presence of clinically and mammographically occult disease using breast MRI in a cohort of cancer patients undergoing contralateral prophylactic mastectomy (CPM) and the utmost indication of axillary assessment (sentinel node biopsy (SLNB)) for this side. A retrospective review of patients with unilateral invasive breast cancer or ductal carcinoma in situ (DCIS) from institutional MRI registry data (2004–2010) was conducted. Characteristics of patients undergoing CPM with breast MRI obtained less than 6 month before surgery were evaluated. A total of 2322 consecutive patients diagnosed with DCIS or stage I to III infiltrating breast cancer underwent preoperative breast MRI. Of these, 1376 patients (59.2%) had contralateral clinical breast exam and mammography without abnormalities; and 116 patients (4.9%) underwent CPM (28 excluded patients had breast MRI more than 6 months before CPM). The mean age of the 88 patients was 49 years (range 28–76 years). Two (2.3%) DCIS identified on surgical pathology specimen were not depicted by MRI and the 5 mm T1N0 invasive cancer (1.1%) was identified on MRI. Preoperative MRI showed 95% accuracy to demonstrate absence of occult disease with negative predicted value (NPV) of 98% (95% CI: 91.64–99.64%). Occult disease was present in 3.4% of CPM. MRI accurately identified the case of invasive cancer in this cohort. The high negative predictive value suggests that MRI can be used to select patients without consideration of SLNB for the contralateral side.
format Online
Article
Text
id pubmed-4924360
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-49243602016-06-29 The value of breast MRI in high‐risk patients with newly diagnosed breast cancer to exclude invasive disease in the contralateral prophylactic mastectomy: Is there a role to choose wisely patients for sentinel node biopsy? Freitas, Vivianne Crystal, Pavel Kulkarni, Supriya R. Ghai, Sandeep Bukhanov, Karina Escallon, Jaime Scaranelo, Anabel M. Cancer Med Clinical Cancer Research The aim of this study was to evaluate the presence of clinically and mammographically occult disease using breast MRI in a cohort of cancer patients undergoing contralateral prophylactic mastectomy (CPM) and the utmost indication of axillary assessment (sentinel node biopsy (SLNB)) for this side. A retrospective review of patients with unilateral invasive breast cancer or ductal carcinoma in situ (DCIS) from institutional MRI registry data (2004–2010) was conducted. Characteristics of patients undergoing CPM with breast MRI obtained less than 6 month before surgery were evaluated. A total of 2322 consecutive patients diagnosed with DCIS or stage I to III infiltrating breast cancer underwent preoperative breast MRI. Of these, 1376 patients (59.2%) had contralateral clinical breast exam and mammography without abnormalities; and 116 patients (4.9%) underwent CPM (28 excluded patients had breast MRI more than 6 months before CPM). The mean age of the 88 patients was 49 years (range 28–76 years). Two (2.3%) DCIS identified on surgical pathology specimen were not depicted by MRI and the 5 mm T1N0 invasive cancer (1.1%) was identified on MRI. Preoperative MRI showed 95% accuracy to demonstrate absence of occult disease with negative predicted value (NPV) of 98% (95% CI: 91.64–99.64%). Occult disease was present in 3.4% of CPM. MRI accurately identified the case of invasive cancer in this cohort. The high negative predictive value suggests that MRI can be used to select patients without consideration of SLNB for the contralateral side. John Wiley and Sons Inc. 2016-03-18 /pmc/articles/PMC4924360/ /pubmed/26992816 http://dx.doi.org/10.1002/cam4.663 Text en © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Freitas, Vivianne
Crystal, Pavel
Kulkarni, Supriya R.
Ghai, Sandeep
Bukhanov, Karina
Escallon, Jaime
Scaranelo, Anabel M.
The value of breast MRI in high‐risk patients with newly diagnosed breast cancer to exclude invasive disease in the contralateral prophylactic mastectomy: Is there a role to choose wisely patients for sentinel node biopsy?
title The value of breast MRI in high‐risk patients with newly diagnosed breast cancer to exclude invasive disease in the contralateral prophylactic mastectomy: Is there a role to choose wisely patients for sentinel node biopsy?
title_full The value of breast MRI in high‐risk patients with newly diagnosed breast cancer to exclude invasive disease in the contralateral prophylactic mastectomy: Is there a role to choose wisely patients for sentinel node biopsy?
title_fullStr The value of breast MRI in high‐risk patients with newly diagnosed breast cancer to exclude invasive disease in the contralateral prophylactic mastectomy: Is there a role to choose wisely patients for sentinel node biopsy?
title_full_unstemmed The value of breast MRI in high‐risk patients with newly diagnosed breast cancer to exclude invasive disease in the contralateral prophylactic mastectomy: Is there a role to choose wisely patients for sentinel node biopsy?
title_short The value of breast MRI in high‐risk patients with newly diagnosed breast cancer to exclude invasive disease in the contralateral prophylactic mastectomy: Is there a role to choose wisely patients for sentinel node biopsy?
title_sort value of breast mri in high‐risk patients with newly diagnosed breast cancer to exclude invasive disease in the contralateral prophylactic mastectomy: is there a role to choose wisely patients for sentinel node biopsy?
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924360/
https://www.ncbi.nlm.nih.gov/pubmed/26992816
http://dx.doi.org/10.1002/cam4.663
work_keys_str_mv AT freitasvivianne thevalueofbreastmriinhighriskpatientswithnewlydiagnosedbreastcancertoexcludeinvasivediseaseinthecontralateralprophylacticmastectomyistherearoletochoosewiselypatientsforsentinelnodebiopsy
AT crystalpavel thevalueofbreastmriinhighriskpatientswithnewlydiagnosedbreastcancertoexcludeinvasivediseaseinthecontralateralprophylacticmastectomyistherearoletochoosewiselypatientsforsentinelnodebiopsy
AT kulkarnisupriyar thevalueofbreastmriinhighriskpatientswithnewlydiagnosedbreastcancertoexcludeinvasivediseaseinthecontralateralprophylacticmastectomyistherearoletochoosewiselypatientsforsentinelnodebiopsy
AT ghaisandeep thevalueofbreastmriinhighriskpatientswithnewlydiagnosedbreastcancertoexcludeinvasivediseaseinthecontralateralprophylacticmastectomyistherearoletochoosewiselypatientsforsentinelnodebiopsy
AT bukhanovkarina thevalueofbreastmriinhighriskpatientswithnewlydiagnosedbreastcancertoexcludeinvasivediseaseinthecontralateralprophylacticmastectomyistherearoletochoosewiselypatientsforsentinelnodebiopsy
AT escallonjaime thevalueofbreastmriinhighriskpatientswithnewlydiagnosedbreastcancertoexcludeinvasivediseaseinthecontralateralprophylacticmastectomyistherearoletochoosewiselypatientsforsentinelnodebiopsy
AT scaraneloanabelm thevalueofbreastmriinhighriskpatientswithnewlydiagnosedbreastcancertoexcludeinvasivediseaseinthecontralateralprophylacticmastectomyistherearoletochoosewiselypatientsforsentinelnodebiopsy
AT freitasvivianne valueofbreastmriinhighriskpatientswithnewlydiagnosedbreastcancertoexcludeinvasivediseaseinthecontralateralprophylacticmastectomyistherearoletochoosewiselypatientsforsentinelnodebiopsy
AT crystalpavel valueofbreastmriinhighriskpatientswithnewlydiagnosedbreastcancertoexcludeinvasivediseaseinthecontralateralprophylacticmastectomyistherearoletochoosewiselypatientsforsentinelnodebiopsy
AT kulkarnisupriyar valueofbreastmriinhighriskpatientswithnewlydiagnosedbreastcancertoexcludeinvasivediseaseinthecontralateralprophylacticmastectomyistherearoletochoosewiselypatientsforsentinelnodebiopsy
AT ghaisandeep valueofbreastmriinhighriskpatientswithnewlydiagnosedbreastcancertoexcludeinvasivediseaseinthecontralateralprophylacticmastectomyistherearoletochoosewiselypatientsforsentinelnodebiopsy
AT bukhanovkarina valueofbreastmriinhighriskpatientswithnewlydiagnosedbreastcancertoexcludeinvasivediseaseinthecontralateralprophylacticmastectomyistherearoletochoosewiselypatientsforsentinelnodebiopsy
AT escallonjaime valueofbreastmriinhighriskpatientswithnewlydiagnosedbreastcancertoexcludeinvasivediseaseinthecontralateralprophylacticmastectomyistherearoletochoosewiselypatientsforsentinelnodebiopsy
AT scaraneloanabelm valueofbreastmriinhighriskpatientswithnewlydiagnosedbreastcancertoexcludeinvasivediseaseinthecontralateralprophylacticmastectomyistherearoletochoosewiselypatientsforsentinelnodebiopsy